Results 101 to 110 of about 1,772,527 (156)
ABSTRACT Wilms Tumour (WT), the most common kidney cancer in children, presents features of altered kidney development and frequently exhibits molecular alterations at the 11p15.5 imprinted locus, affecting the IGF2 and H19 genes, which contribute to tumour growth and predisposition.
Abu Saadat +14 more
wiley +1 more source
Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy [PDF]
Altres ajuts: Cellex Foundation, CEL007; Asociación Española Contra el Cáncer, AC18/000002Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies ...
Molero, Antonieta +34 more
core +1 more source
Objective: To assess the clinical and non-clinical factors leading to non-compliance or discontinuation of hypomethylating agent therapy in patients of myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Zoya Ziad +6 more
doaj +1 more source
PANoptosis in the pathogenesis of myelodysplastic syndromes
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla +4 more
wiley +1 more source
Higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) of the elderly exhibit several commonalities, including first line treatment with hypomethylating agents (HMA) like azacitidine (AZA) or decitabine (DAC).
Uwe Platzbecker +2 more
core +1 more source
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu +7 more
wiley +1 more source
Primary endpoint treatment-change-free survival (TCFS), defined as time from randomization to death or initiation of a new disease-modifying treatment in the phase 2 DELTA trial. AML, acute myeloid leukemia; EPAG, eltrombopag; HMA, hypomethylating agents;
Sockel, Katja;Röllig, Christoph;Mütherig, Anke;Crysandt, Martina;Zukunft, Sven;Herbst, Regina;Noppeney, Richard;Schäfer-Eckardt, Kerstin;Kaufmann, Martin;Oelschlaegel, Uta;Fiebig, Frank;Giagounides, Aristoteles;Götze, Katharina;Scholl, Sebastian;Lück, Andreas;Rieger, Kathrin;Geer, Thomas;Kiewe, Philipp;Müller-Tidow, Carsten;Serve, Hubert;Baldus, Claudia D;Kaiser, Ulrich;Mahlmann, Stefan;Schmidt, Burkhard;Parmentier, Stefani;Illmer, Thomas;Seggewiss-Bernhardt, Ruth;Kiani, Alexander;Linde, Hartmut;Dürk, Heinz;Kramer, Michael;Kunadt, Desiree;Schmidt-Brücken, Katharina;Balaian, Ekaterina;Trautmann-Grill, Karolin;Ruhnke, Leo;Middeke, Jan Moritz;von Bonin, Malte;Ehninger, Gerhard;Thiede, Christian;Bornhäuser, Martin;Schetelig, Johannes;Platzbecker, Uwe
core +1 more source
ABSTRACT Background Venetoclax‐based regimens (VEN) have been widely adopted as frontline therapeutic options for elderly patients with acute myeloid leukemia (AML). However, comprehensive real‐world comparisons of VEN with conventional intensive or reduced‐intensity chemotherapy remain limited.
Jiadan Sheng +54 more
wiley +1 more source
ABSTRACT Blastic plasmacytoid dendritic neoplasm (BPDCN) is an aggressive and rare hematological malignancy. Treatment options for frail, elderly patients with BPDCN are limited. Herein, we report the novel use of cytarabine and venetoclax therapy in an elderly patient with BPDCN, which extended his overall survival and improved his quality of life.
Luc M. Murray‐Jones +2 more
wiley +1 more source

